Product
IVIg
2 clinical trials
2 indications
Indication
HypophosphatasiaClinical trial
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)Status: Not yet recruiting, Estimated PCD: 2028-04-28
Clinical trial
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating PolyneuropathyStatus: Recruiting, Estimated PCD: 2025-11-05